Switch theme
Sign up to access all valuation multiples
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
2019
75
LTM Revenue $57.5M
LTM EBITDA -$73.9M
$101M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Septerna has a last 12-month revenue (LTM) of $57.5M and a last 12-month EBITDA of -$73.9M.
In the most recent fiscal year, Septerna achieved revenue of $1.1M and an EBITDA of -$79.4M.
Septerna expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Septerna valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $57.5M | XXX | $1.1M | XXX | XXX | XXX |
| Gross Profit | $57.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$73.9M | XXX | -$79.4M | XXX | XXX | XXX |
| EBITDA Margin | -129% | XXX | -7388% | XXX | XXX | XXX |
| EBIT | -$46.2M | XXX | -$80.8M | XXX | XXX | XXX |
| EBIT Margin | -80% | XXX | -7518% | XXX | XXX | XXX |
| Net Profit | -$35.5M | XXX | -$71.8M | XXX | XXX | XXX |
| Net Margin | -62% | XXX | -6679% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Septerna's stock price is $9.
Septerna has current market cap of $412M, and EV of $101M.
See Septerna trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $101M | $412M | XXX | XXX | XXX | XXX | $-3.91 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Septerna has market cap of $412M and EV of $101M.
Septerna's trades at 94.1x EV/Revenue multiple, and -1.3x EV/EBITDA.
Equity research analysts estimate Septerna's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Septerna has a P/E ratio of -11.6x.
See valuation multiples for Septerna and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $412M | XXX | $412M | XXX | XXX | XXX |
| EV (current) | $101M | XXX | $101M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 94.1x | XXX | XXX | XXX |
| EV/EBITDA | -1.4x | XXX | -1.3x | XXX | XXX | XXX |
| EV/EBIT | -2.2x | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -11.6x | XXX | -5.7x | XXX | XXX | XXX |
| EV/FCF | -64.0x | XXX | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSepterna's last 12 month revenue growth is 63%
Septerna's revenue per employee in the last FY averaged $14K, while opex per employee averaged $1.1M for the same period.
Septerna's rule of 40 is -29541% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Septerna's rule of X is 28% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Septerna and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 63% | XXX | 439% | XXX | XXX | XXX |
| EBITDA Margin | -129% | XXX | -7388% | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -29541% | XXX | -7325% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $14K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6078% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 7618% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Septerna acquired XXX companies to date.
Last acquisition by Septerna was XXXXXXXX, XXXXX XXXXX XXXXXX . Septerna acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Septerna founded? | Septerna was founded in 2019. |
| Where is Septerna headquartered? | Septerna is headquartered in United States of America. |
| How many employees does Septerna have? | As of today, Septerna has 75 employees. |
| Who is the CEO of Septerna? | Septerna's CEO is Dr. Jeffrey T. Finer, M.D.,PhD. |
| Is Septerna publicy listed? | Yes, Septerna is a public company listed on NAS. |
| What is the stock symbol of Septerna? | Septerna trades under SEPN ticker. |
| When did Septerna go public? | Septerna went public in 2024. |
| Who are competitors of Septerna? | Similar companies to Septerna include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Septerna? | Septerna's current market cap is $412M |
| What is the current revenue of Septerna? | Septerna's last 12 months revenue is $57.5M. |
| What is the current revenue growth of Septerna? | Septerna revenue growth (NTM/LTM) is 63%. |
| What is the current EV/Revenue multiple of Septerna? | Current revenue multiple of Septerna is 1.8x. |
| Is Septerna profitable? | Yes, Septerna is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Septerna? | Septerna's last 12 months EBITDA is -$73.9M. |
| What is Septerna's EBITDA margin? | Septerna's last 12 months EBITDA margin is -129%. |
| What is the current EV/EBITDA multiple of Septerna? | Current EBITDA multiple of Septerna is -1.4x. |
| What is the current FCF of Septerna? | Septerna's last 12 months FCF is -$1.6M. |
| What is Septerna's FCF margin? | Septerna's last 12 months FCF margin is -3%. |
| What is the current EV/FCF multiple of Septerna? | Current FCF multiple of Septerna is -64.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
